Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recAP phase 2 study in sepsis-associated acute kidney injury
2014-000761-40Phase 2Completed
- Sponsor
- AM-Pharma
- Start
- Aug 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ilofotase alfa in sepsis-associated acute kidney injury (S-AKI) (4 arms), sponsored by AM-Pharma. Started Aug 2014; status: completed.
02
Drugs
ilofotase alfa
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on 2014-000761-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000761-40.